PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Cited by 11 Publications

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

5 Customer Reviews

After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.
Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.
Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	M2XwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\GTHh7UUN3ME2wMlgzODJ2IN88US=>	NGL1PJpUSU6JRWK=
UACC-893	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTVwMUm4PFYh\|ryP	MmLQV2FPT0WU
A427	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHCTWM2OD13LkeyOVY4KM7:TR?=	M1XjdHNCVkeHUh?=
OCUB-M	NF:2T4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTZwNk[xNFIh\|ryP	MoDCV2FPT0WU
SW684	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjpTHNKSzVyPUeuOVIzPjhizszN	M2jaNHNCVkeHUh?=
SK-LMS-1	M4CxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXlTWM2OD17LkCxN\|AzKM7:TR?=	NYn6SGNvW0GQR1XS
CP50-MEL-B	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPve4tyUUN3ME25MlMxPDF7IN88US=>	NGfIOI9USU6JRWK=
NCI-H1651	NETTWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\RS4JKSzVyPUGwMlAzPzZizszN	NIXJVZFUSU6JRWK=
ABC-1	M{HTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nKWGlEPTB;MUCuNVA{PyEQvF2=	M1;rN3NCVkeHUh?=
OE19	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmG5TWM2OD1zMD6xO\|M{KM7:TR?=	NEX0WXBUSU6JRWK=
DSH1	NEXRRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLDcGlKSzVyPUGwMlg5PzlizszN	NFraXYtUSU6JRWK=
SW13	NYD2c\|lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjuTWM2OD1zMT65N\|E6KM7:TR?=	M3OwXXNCVkeHUh?=
MDA-MB-453	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPnPZdKSzVyPUGyMlE3ODNizszN	NGm4SpVUSU6JRWK=
647-V	M2nVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTF{LkO1PFIh\|ryP	NWTKZ5RzW0GQR1XS
NCI-H2342	NY\0O\|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTF{LkO5PVUh\|ryP	M4nndnNCVkeHUh?=
LB2241-RCC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\MdIxKSzVyPUGyMlU4PzlizszN	NHHY[YJUSU6JRWK=
UACC-257	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVmzbIRGUUN3ME2xN{41PDV\|IN88US=>	MYDTRW5ITVJ?
NCI-H661	M2DrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1uyd2lEPTB;MUOuOlQ1QSEQvF2=	MmnjV2FPT0WU
FADU	NEDjdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fUfGlEPTB;MUOuOlk6OiEQvF2=	NEDaNFJUSU6JRWK=
A2780	M3\sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq4fnV7UUN3ME2xN{45ODRzIN88US=>	Mni3V2FPT0WU
NCI-H1793	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkP5TWM2OD1zND60NFg2KM7:TR?=	MVLTRW5ITVJ?
TE-8	M3LZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTF3LkO0OlUh\|ryP	MWDTRW5ITVJ?
HGC-27	NWnIT3BXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvITWM2OD1zNj6xOlQ1KM7:TR?=	Mom1V2FPT0WU
MMAC-SF	M4HobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTF5LkO3Nlch\|ryP	NYXpUZBnW0GQR1XS
Calu-6	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTF6LkG1NVMh\|ryP	M{WzVnNCVkeHUh?=
HUTU-80	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonjTWM2OD1zOD6zPVU6KM7:TR?=	MXnTRW5ITVJ?
SAS	NH7yUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTF6Lk[0OVUh\|ryP	M1HMenNCVkeHUh?=
IST-MES1	MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjZWmlwUUN3ME2xPE43PTB6IN88US=>	MknDV2FPT0WU
C3A	NUezXlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mln3TWM2OD1zOD63PVE6KM7:TR?=	Mmn5V2FPT0WU
ES3	NWO3[oFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF6LkizOlQh\|ryP	NYm0dFVuW0GQR1XS
HSC-2	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETMemRKSzVyPUG5MlY2PDFizszN	MmKzV2FPT0WU
T47D	NHPWSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoS4TWM2OD1{MD6xOFg2KM7:TR?=	Mn\WV2FPT0WU
EW-7	NWTGfnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXizZlZIUUN3ME2yNE45PTh6IN88US=>	MWTTRW5ITVJ?
LN-405	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETK[IZKSzVyPUKwMlg6PjVizszN	NWfYfI1xW0GQR1XS
U031	NXTVU4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJzLkS4NFIh\|ryP	NXr4PI5WW0GQR1XS
A549	NHu1RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zPWGlEPTB;MkGuPFQ6OSEQvF2=	MV7TRW5ITVJ?
RMG-I	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPMTWM2OD1{Mj6yOlY5KM7:TR?=	MUHTRW5ITVJ?
BT-474	M3;lSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGz[INEUUN3ME2yNk43PTVzIN88US=>	M3GzdHNCVkeHUh?=
NB69	M4rPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{WzUWlEPTB;MkOuNVUzKM7:TR?=	NX2yNW9rW0GQR1XS
NB7	M3:3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fwNmlEPTB;MkSuNVg5KM7:TR?=	NFPscINUSU6JRWK=
HCC1569	NFL1ZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTJ2Lk[xNlUh\|ryP	M1G5W3NCVkeHUh?=
MEL-JUSO	NVrnUJBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrIc2o5UUN3ME2yOE43QTB6IN88US=>	NGnpOnpUSU6JRWK=
MDA-MB-175-VII	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJ3LkK1NVch\|ryP	NWCx[lNPW0GQR1XS
HCC1419	M1rRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHoPVNPUUN3ME2yOU43ODB\|IN88US=>	M4rzW3NCVkeHUh?=
Ca9-22	NYL2NldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XId2lEPTB;MkWuOlQ{OiEQvF2=	M3HnbHNCVkeHUh?=
KGN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHexdmNKSzVyPUK1Mlc2PDdizszN	MYnTRW5ITVJ?
LB373-MEL-D	M3jzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\uUGlEPTB;Mk[uNVk{QCEQvF2=	NVWxe2pWW0GQR1XS
NCI-H1755	MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTJ4Lki4OFEh\|ryP	NIXrU5pUSU6JRWK=
D-423MG	NHj6S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF62TFJKSzVyPUK3MlA4OTVizszN	NEC0R4lUSU6JRWK=
DK-MG	M1LSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVWwcmR{UUN3ME2yPE44QDR4IN88US=>	NITpSXBUSU6JRWK=
NCI-H1623	NFryOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXCOGl2UUN3ME2yPE45OzR{IN88US=>	MnPqV2FPT0WU
KU-19-19	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvRTWM2OD1{OD65PVUh\|ryP	Ml3GV2FPT0WU
C-33-A	NFz5e4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTJ7LkKxPVgh\|ryP	MWnTRW5ITVJ?
SCC-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLzTWM2OD1\|MD6zN\|U1KM7:TR?=	MUfTRW5ITVJ?
MG-63	NXLa[4JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj6TWM2OD1\|MD61PVk1KM7:TR?=	MYrTRW5ITVJ?
LNCaP-Clone-FGC	NGrxWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXMbHZKSzVyPUOxMlQ6OjFizszN	NX6yeWNnW0GQR1XS
CAPAN-1	NWXlS49qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzhelBKSzVyPUOxMlUzQDZizszN	Mnn2V2FPT0WU
GI-ME-N	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTNzLkWzOVMh\|ryP	NWjxdJFmW0GQR1XS
RERF-LC-MS	NW\kb3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j6[GlEPTB;M{KuOlc1PyEQvF2=	MVrTRW5ITVJ?
KLE	NF\1SItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHVSFZKSzVyPUOzMlQ{OzRizszN	MULTRW5ITVJ?
KNS-81-FD	NHzke5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN\|LkWwNFgh\|ryP	NEm3WYxUSU6JRWK=
DOK	NFH0N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTN2Lk[2NVIh\|ryP	NEPxUlVUSU6JRWK=
ACHN	NHe1V4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rMemlEPTB;M{WuNVU5QCEQvF2=	NUnadJJiW0GQR1XS
KYSE-520	M2rqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW4TWM2OD1\|NT6yN\|YyKM7:TR?=	MVLTRW5ITVJ?
SBC-5	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTN3LkWxNVYh\|ryP	NXnBNoJlW0GQR1XS
NCI-H28	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[yZYFKSzVyPUO1MlY3QTVizszN	MnuxV2FPT0WU
ES7	M1XxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjhOZlKSzVyPUO2MlIzPDlizszN	NXjv[ndTW0GQR1XS
A172	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTN4LkSxPFch\|ryP	NGr1ZW5USU6JRWK=
UM-UC-3	M1zRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTN5Lki3OFYh\|ryP	NUWwR4ZXW0GQR1XS
LXF-289	M2q5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPpTmVKSzVyPUO4MlAxPDdizszN	MVfTRW5ITVJ?
KP-4	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjIem4{UUN3ME2zPE41PzN7IN88US=>	MYnTRW5ITVJ?
TE-1	NUHESVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nQSGlEPTB;M{muOlU5QSEQvF2=	MVrTRW5ITVJ?
G-402	M1:zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTRyLkC2NUDPxE1?	NHzBbZFUSU6JRWK=
786-0	NGHBVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrnb3o{UUN3ME20NE46ODl4IN88US=>	MUTTRW5ITVJ?
K5	NYezS2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvYcVhKSzVyPUSxMlM3QDZizszN	NIrKb3BUSU6JRWK=
SK-N-DZ	NX7PU2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7aWGtFUUN3ME20NU4{QDJ\|IN88US=>	MXvTRW5ITVJ?
OVCAR-4	NWfCdFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFexNmFKSzVyPUSxMlc2PjhizszN	MkCxV2FPT0WU
T84	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTR{LkGyOlMh\|ryP	MYPTRW5ITVJ?
GCIY	M2Xz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrRTZN4UUN3ME20N{4xQDB\|IN88US=>	NInSPG5USU6JRWK=
BB49-HNC	NYTnPG9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\sTWM2OD12Mz6zN\|Q5KM7:TR?=	MXHTRW5ITVJ?
SNU-C2B	NX\nVGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTR\|Lk[0N\|Yh\|ryP	NVvvfo9vW0GQR1XS
TE-6	NUj0bY9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDsd2VKSzVyPUSzMlg5QTRizszN	NHnZT49USU6JRWK=
23132-87	M3m2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTR2LkK5O\|gh\|ryP	MoXSV2FPT0WU
DMS-53	M{Hybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTR2LkOzPFQh\|ryP	M3roN3NCVkeHUh?=
ONS-76	Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfVNpJKSzVyPUS0Mlc3PjFizszN	NYOyfHJNW0GQR1XS
DMS-273	NFHHV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjybJdKSzVyPUS0Mlk1OyEQvF2=	M1:we3NCVkeHUh?=
COLO-824	M4PSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTR3Lki3O\|Uh\|ryP	MUTTRW5ITVJ?
DMS-114	NX75O4JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;NPGlEPTB;NEWuPFkzPyEQvF2=	MYXTRW5ITVJ?
YKG-1	NXfkNINET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7xNItKSzVyPUS2MlA{PTVizszN	M4\mVHNCVkeHUh?=
RH-18	NFzrbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTR4LkO3N\|Mh\|ryP	NW[5OGxXW0GQR1XS
NCI-H1355	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHDenNKSzVyPUS2MlYyQCEQvF2=	MnjBV2FPT0WU
NCI-H2170	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjoUYpKSzVyPUS3Mlc2QDRizszN	Mlm0V2FPT0WU
OC-314	NHHPZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nDUmlEPTB;NEeuPFQ4QCEQvF2=	NH7sNlBUSU6JRWK=
NCI-H2030	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj3eFlKSzVyPUS3Mlg6ODZizszN	NX3sbmgxW0GQR1XS
22RV1	NHTmb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jRU2lEPTB;NEeuPVAyPSEQvF2=	MoLnV2FPT0WU
G-401	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXHVGl5UUN3ME20PE41PDF3IN88US=>	NFv2SHVUSU6JRWK=
YAPC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTR7LkiwO\|Mh\|ryP	NGLlVldUSU6JRWK=
SW1573	NGTNcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWC1cnEzUUN3ME21NE4zPDN3IN88US=>	MUXTRW5ITVJ?
COLO-792	NIHGfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn3eYVKSzVyPUWwMlYzOzdizszN	MYDTRW5ITVJ?
KNS-62	M4eyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTVyLke1NFgh\|ryP	NWXqO3ZVW0GQR1XS
NB5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;ieHE{UUN3ME21NU41PTB7IN88US=>	MXTTRW5ITVJ?
CP66-MEL	NFPCUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknWTWM2OD13MT62OFA5KM7:TR?=	MWfTRW5ITVJ?
CaR-1	MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LBbmlEPTB;NUKuNFYxPiEQvF2=	MWHTRW5ITVJ?
CAL-54	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTV{LkGxNFIh\|ryP	MYTTRW5ITVJ?
8305C	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jHeWlEPTB;NUKuN\|E2KM7:TR?=	M3z5[HNCVkeHUh?=
Calu-3	NFLrcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnUUGo3UUN3ME21Nk4{PzN\|IN88US=>	MkPBV2FPT0WU
AU565	M33lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTV{LkW1NFkh\|ryP	M3\CR3NCVkeHUh?=
CW-2	M1TDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPoTWM2OD13Mj64OlU1KM7:TR?=	NXX4bZlFW0GQR1XS
BEN	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W0fWlEPTB;NUOuO\|g3OiEQvF2=	MkfxV2FPT0WU
NCI-H1975	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXzTWM2OD13Mz64PVY3KM7:TR?=	MYLTRW5ITVJ?
HCT-116	NFe0VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonoTWM2OD13ND6wN\|I4KM7:TR?=	Mnz6V2FPT0WU
SH-4	M2fHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X4NmlEPTB;NUSuNVM5KM7:TR?=	Mn7BV2FPT0WU
NCI-H1693	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3MZ3BKSzVyPUW0MlIyODNizszN	MVvTRW5ITVJ?
BPH-1	M3;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7adohKSzVyPUW1MlI5QTJizszN	MmX5V2FPT0WU
CAMA-1	M3SzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\YTWM2OD13NT64NVE3KM7:TR?=	M2XucXNCVkeHUh?=
A388	NYrkd5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTV4LkC5PFUh\|ryP	MU\TRW5ITVJ?
C2BBe1	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG0TWM2OD13Nj6yOlM1KM7:TR?=	MnrhV2FPT0WU
GAMG	NXSyPGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHLOJJKSzVyPUW2MlU6PTVizszN	NEL6SFFUSU6JRWK=
MKN28	NGjFTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XpVmlEPTB;NU[uPFAyOyEQvF2=	NFO2W\|dUSU6JRWK=
VA-ES-BJ	NF\EOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[yTWM2OD13Nj64O\|Q2KM7:TR?=	Mm\qV2FPT0WU
HuCCT1	M3LLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlX6TWM2OD13Nz6wOFkzKM7:TR?=	MVHTRW5ITVJ?
BFTC-905	MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7aTnZIUUN3ME21O{4zQDl6IN88US=>	MoCzV2FPT0WU
LS-123	NYqzfVRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTV5LkW2Olgh\|ryP	MWfTRW5ITVJ?
LB996-RCC	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LUVWlEPTB;NUiuNFI5PyEQvF2=	NVz4eWhqW0GQR1XS
NCI-H1048	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTwVFlpUUN3ME21PE4zOTh6IN88US=>	NID5d\|VUSU6JRWK=
COR-L105	NVv2TIExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEWyNWNKSzVyPUW4Mlc{OzdizszN	MnjjV2FPT0WU
OVCAR-8	NGLkelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkL5TWM2OD13OT6xO\|E3KM7:TR?=	NWTxRnpCW0GQR1XS
SK-N-FI	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\aVHZZUUN3ME21PU4{OjB5IN88US=>	M4fJUnNCVkeHUh?=
MES-SA	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTV7LkS1NFkh\|ryP	Mk\KV2FPT0WU
SCC-9	NVTpcIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PCWWlEPTB;NUmuOFc2OyEQvF2=	MUfTRW5ITVJ?
EFO-27	NUHIUWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITaWGRKSzVyPUW5Mlk1OyEQvF2=	M{XDTnNCVkeHUh?=
GT3TKB	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXafodKSzVyPU[wMlYxPDhizszN	MUTTRW5ITVJ?
HCC38	NXO4XYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTZzLkSzO\|kh\|ryP	NV\RSJBSW0GQR1XS
MLMA	M4nidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LSeGlEPTB;NkGuOlE3OyEQvF2=	MoDUV2FPT0WU
D-566MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfXflZrUUN3ME22N{42OjJ2IN88US=>	NHrOT5ZUSU6JRWK=
SF295	NWKx[mtKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XkOmlEPTB;NkOuOlY2PSEQvF2=	MX\TRW5ITVJ?
ES4	M1Oycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXSepd{UUN3ME22OE41PzF7IN88US=>	NH3TdphUSU6JRWK=
CAKI-1	NVTTbVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzaTWM2OD14ND61O\|IyKM7:TR?=	NGXuVpVUSU6JRWK=
OAW-28	NUPxZldCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{H0[WlEPTB;NkSuPVY1PyEQvF2=	MULTRW5ITVJ?
NCI-H460	NHLWXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:1WGlEPTB;NkWuNFg6PyEQvF2=	NXnTSHJYW0GQR1XS
JAR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV2wW2RXUUN3ME22OU42PTF4IN88US=>	NW\5[2RSW0GQR1XS
SNU-449	M4\wRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjxOYRKSzVyPU[1Mlc3OTZizszN	NV;5bnVlW0GQR1XS
D-392MG	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTZ3Lkm0N\|Qh\|ryP	MlHaV2FPT0WU
EW-22	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYX0enZxUUN3ME22Ok4{QTVizszN	NVq4fIVNW0GQR1XS
GCT	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTZ5LkC0OFMh\|ryP	MV;TRW5ITVJ?
NOS-1	M2\2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXKTWM2OD14Nz62PFY4KM7:TR?=	NHjKXVdUSU6JRWK=
RH-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTZ6LkW1OVkh\|ryP	MXLTRW5ITVJ?
HuH-7	NWf0bGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTZ7LkGwNFIh\|ryP	MULTRW5ITVJ?
NUGC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjTbW5EUUN3ME23NE46PjR2IN88US=>	MY\TRW5ITVJ?
IST-SL1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTdzLkKzNlQh\|ryP	MmLLV2FPT0WU
SHP-77	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorCTWM2OD15Mj6xNVkh\|ryP	M{HKXXNCVkeHUh?=
SW1116	NEPyeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrMdoxrUUN3ME23Nk4yPDB5IN88US=>	NF[4ZW9USU6JRWK=
LK-2	M1fpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\STWM2OD15Mj64OlEzKM7:TR?=	NInjeGtUSU6JRWK=
U-2-OS	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\XfoVKSzVyPUezMlE5OjhizszN	MXjTRW5ITVJ?
KYSE-150	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTd\|Lk[xNVgh\|ryP	MnHsV2FPT0WU
U251	NHHZRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHFTWM2OD15Mz64NVY5KM7:TR?=	M1zVWnNCVkeHUh?=
HT-1080	NHq3RWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTd2LkK1O\|Qh\|ryP	NHi2O2VUSU6JRWK=
NCI-H1437	NYjH[HdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzDZ4ZKSzVyPUe0MlY{OjZizszN	M124e3NCVkeHUh?=
HPAF-II	NYXWXpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vISmlEPTB;N{SuOlQyPSEQvF2=	NH:4[W5USU6JRWK=
Becker	M17Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLlUHhKSzVyPUe1MlEyODVizszN	MlHSV2FPT0WU
PANC-10-05	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTd3LkK4OlUh\|ryP	M{GxdHNCVkeHUh?=
TYK-nu	NWXFenNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTZTWM2OD15NT6zNVAzKM7:TR?=	MVPTRW5ITVJ?
SKG-IIIa	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXlR3Q4UUN3ME23OU4{OzRzIN88US=>	NEjCRlFUSU6JRWK=
NCI-H1993	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLK[YRKSzVyPUe1Mlc{QTdizszN	NGr4T\|FUSU6JRWK=
S-117	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K5dGlEPTB;N{WuO\|U2KM7:TR?=	Mn31V2FPT0WU
HuO9	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\yZldKSzVyPUe2MlAxPDhizszN	MkHMV2FPT0WU
CAL-51	M{DmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDFTYFKSzVyPUe2MlExODZizszN	NI\SeldUSU6JRWK=
BT-20	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrFPXhvUUN3ME23Ok4zOTZ6IN88US=>	MnPNV2FPT0WU
LB831-BLC	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWL1R3BbUUN3ME23Ok4{OjF5IN88US=>	MkH3V2FPT0WU
LB1047-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[we\|VCUUN3ME23Ok44PjF7IN88US=>	NVnWc5U5W0GQR1XS
ES8	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S2[mlEPTB;N{iuNFA4OyEQvF2=	NETITHNUSU6JRWK=
UMC-11	M1vIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M332XmlEPTB;N{iuNFg5PCEQvF2=	NWXWPFRXW0GQR1XS
NCI-H226	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLLb4dYUUN3ME23PE4yOzF3IN88US=>	MUTTRW5ITVJ?
IGROV-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnUNZVYUUN3ME23PE42PTVizszN	NGHRemFUSU6JRWK=
BHY	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITPc3ZKSzVyPUe5MlU6PiEQvF2=	M3L1c3NCVkeHUh?=
MKN45	NXvzeZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL5cGxKSzVyPUiwMlMyPzRizszN	MVLTRW5ITVJ?
IA-LM	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrHTWM2OD16MD6zOVEyKM7:TR?=	M{j6TXNCVkeHUh?=
WM-115	NXzh[\|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXG3Z3pKUUN3ME24NU41OTF2IN88US=>	MlTPV2FPT0WU
VMRC-RCZ	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\HTWM2OD16MT60OFI2KM7:TR?=	NVr6TIFsW0GQR1XS
NCI-H2291	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRThzLk[4OFIh\|ryP	NHfzV4dUSU6JRWK=
MCF7	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTh\|LkK4PVch\|ryP	NV:xeWl7W0GQR1XS
639-V	M2rUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:yfIpKSzVyPUi0MlYyOjlizszN	M1vSOHNCVkeHUh?=
RT4	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHVTWM2OD16NT6yOFA{KM7:TR?=	NUXFUZB3W0GQR1XS
NCI-H2405	M4HROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHvTWM2OD16NT6yPVk4KM7:TR?=	M2ni[3NCVkeHUh?=
CAL-33	NVfF[4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fCRWlEPTB;OEWuOlMyPSEQvF2=	NIP6NXlUSU6JRWK=
BT-549	M1P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jubmlEPTB;OEWuPVM5OiEQvF2=	NXLXNWFQW0GQR1XS
HT-1197	M1vJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnQXWZ7UUN3ME24PE4yODd5IN88US=>	NX7hPYNLW0GQR1XS
G-361	NVfNbVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn2OWViUUN3ME24PE4yPDd2IN88US=>	Mn3OV2FPT0WU
LS-411N	M{jTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTh7LkOzPFgh\|ryP	NGPYRWdUSU6JRWK=
HT-144	NUjh[5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;CdGlEPTB;OEmuOVk6OiEQvF2=	MVHTRW5ITVJ?
DJM-1	M1PjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTh7Lki4OFUh\|ryP	NFfnbYpUSU6JRWK=
CAL-12T	NWDQXnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rCO2lEPTB;OUCuO\|g6PSEQvF2=	MY\TRW5ITVJ?
MKN7	M{TOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;FTWM2OD17MT6zOVUyKM7:TR?=	M2DwVnNCVkeHUh?=
HuP-T3	NVPRUZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTl4LkGwNFQh\|ryP	M2HlWXNCVkeHUh?=
SK-MG-1	NGK5XW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHezWo9KSzVyPUm2MlE{PDhizszN	NEG5[GRUSU6JRWK=
NCI-H2347	M1vBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLiUYVKSzVyPUm4MlExPDJizszN	NH;lfHVUSU6JRWK=
SW872	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX4dZNuUUN3ME2xNFAvPDV4IN88US=>	NGPCcoNUSU6JRWK=
COLO-829	M2G3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P1fGlEPTB;MUCwMlU2OyEQvF2=	MYXTRW5ITVJ?
MC-IXC	M2n4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFyMD62NVUh\|ryP	Ml[3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 11 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 11 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)